Company / Cash & Equivalents
BICYCLE THERAPEUTICS PLC Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$628.1M
FY2025
5-year range
$339.2M / $879.5M
FY2021-FY2025
Trend
-28.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 7 years, ranging from $0 in FY2020 to $880M in FY2024.
Based on SEC 10-K filings.
$628M in FY2025 with a 3-year CAGR of +22.8%.
Improved from $526M to $628M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +22.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +22.8%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 28.6% year-over-year.
- Peak cash & equivalents was recorded in FY2024.
- Lowest cash & equivalents in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.98 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $628.1M | -28.6% |
| FY2024 | $879.5M | +67.1% |
| FY2023 | $526.4M | +55.2% |
| FY2022 | $339.2M | -22.7% |
| FY2021 | $438.7M | - |
| FY2020 | $0 | - |
| FY2019 | $0 | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026